Description

Tubal Factor Infertility (TFI) is a leading cause of infertility in women, often resulting from damage to the fallopian tubes due to infections caused by pathogens such as Chlamydia trachomatis. Animal studies using Chlamydia muridarum, a closely related species adapted to infect murine hosts, have provided critical insights into the mechanisms of infection, immune response and subsequent reproductive tract damage. By studying the interactions between C. muridarum and its host, researchers have advanced our understanding of chlamydial pathogenesis and identified potential therapeutic targets to prevent or mitigate TFI. This article describes the mechanisms by which C. muridarum induces TFI and highlights its use in experimental models to study this condition. The pathogenesis of TFI caused by chlamydial infections is a complex interplay of bacterial virulence factors, host immune responses and subsequent tissue damage. Infections with C. muridarum in murine models closely mimic the pathology observed in human infections with C. trachomatis, making it an invaluable tool for studying TFI mechanisms.

Infection and initial immune response

When C. muridarum infects the murine genital tract, it primarily targets epithelial cells lining the reproductive tract, where it undergoes its biphasic developmental cycle. The Elementary Body (EB), the infectious form, enters host cells and transforms into the Reticulate Body (RB), which replicates intracellularly. This intracellular lifestyle allows C. muridarum to evade some host immune defenses, promoting persistent infection. The host’s innate immune response is activated early in the infection, with epithelial cells releasing pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor- Alpha (TNF-α). These cytokines recruit neutrophils and macrophages to the site of infection, initiating an inflammatory response. While inflammation is crucial for controlling bacterial replication, excessive or dysregulated inflammation can lead to collateral tissue damage. C. muridarum infections in mice often result in extensive neutrophil infiltration, which contributes to epithelial damage and fibrosis—a attribute of TFI. Persistent infection and prolonged inflammation are key drivers of TFI. In the case of C. muridarum, repeated cycles of infection and host immune activation lead to the accumulation of inflammatory cells in the fallopian tubes. This results in the release of Reactive Oxygen Species (ROS) and Matrix Metalloproteinases (MMPs), which degrade the extracellular matrix and disrupt the epithelial lining of the fallopian tubes. Over time, this damage can lead to scarring, fibrosis, and the formation of hydrosalpinx (fluid-filled sacs in the fallopian tubes). These structural changes impair the normal function of the fallopian tubes, including ovum pickup, transport, and fertilization, ultimately causing infertility. Animal studies have shown that C. muridarum infections can replicate these pathological outcomes, providing valuable models for understanding the progression of TFI.

Adaptive immunity and its role in pathogenesis

The adaptive immune response, particularly T cell-mediated immunity, plays a dual role in chlamydial infections. While CD4+ T cells are necessary for clearing C. muridarum infection, their overactivation can exacerbate tissue damage. Studies have demonstrated that Th1 responses, characterized by the production of Interferon-Gamma (IFN-γ), are critical for bacterial clearance but can also drive chronic inflammation if not tightly regulated. Conversely, an inadequate regulatory T cell response can fail to resolve inflammation, prolonging tissue damage and scarring. The balance between protective and pathological immune responses is a key determinant of whether an infection resolves without complications or progresses to TFI. Understanding these immune dynamics in C. muridarum models is crucial for developing interventions that minimize tissue damage while effectively clearing the infection. Animal models have been instrumental in elucidating the pathogenesis of chlamydial infections and their link to TFI. C. muridarum, due to its genetic and pathogenic similarities to C. trachomatis, is widely used in murine models to study genital infections and their sequelae. These models have provided valuable insights into the host-pathogen interactions that underlie TFI. Mouse models of C. muridarum genital tract infections mimic the ascending infections observed in human cases. Following intravaginal inoculation, the bacteria ascend to the uterus and fallopian tubes, leading to localized inflammation, epithelial damage and scarring. The progression of these infections in mice mirrors the pathology seen in human C. trachomatis-induced TFI, including the development of hydrosalpinx and tubal blockage. These models allow researchers to study the temporal progression of infection and inflammation, providing a framework for testing therapeutic interventions. For example, studies using C. muridarum have identified key cytokines and immune pathways that contribute to tissue damage, offering potential targets for anti-inflammatory or immune-modulating therapies. Vaccination studies using C. muridarum models have shown promise in inducing protective immunity against chlamydial infections. Subunit vaccines targeting chlamydial antigens, such as the Major Outer Membrane Protein (MOMP), have demonstrated efficacy in reducing bacterial burden and preventing tubal damage in mice. These findings underscore the potential of C. muridarum as a platform for evaluating vaccine candidates. Mouse models of C. muridarum infection are also used to test antimicrobial and anti-inflammatory therapies. Antibiotic treatments, such as azithromycin, effectively clear the infection but may not fully prevent long-term complications like scarring. Combining antibiotics with anti-inflammatory agents or immune modulators has shown promise in mitigating tissue damage and preserving reproductive function. These preclinical studies provide a foundation for translating findings into human clinical trials.